AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6347741 — intervention group
Group type: COMPARATOR
Intervention: Surgical induction (control group)
Number of subjects: 156
Study 6347741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 29175720 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n=131)
Number of subjects: 264
Study 29175720 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (n=133)
Number of subjects: 264
Study 29175720 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 264
Study 26450814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine depletion using an acute phenylalanine/tyrosine depletion drink
Number of subjects: 34
Study 26450814 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid drink (control condition)
Number of subjects: 34
Study 26450814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine depletion
Number of subjects: 34
Study 24686513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training model (N=31) with ongoing expert coaching, video review, and consultation
Number of subjects: 56
Study 24686513 — intervention group
Group type: COMPARATOR
Intervention: Three-day workshop model (N=25)
Number of subjects: 56
Study 22047597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 670-nm laser irradiation, 40 mW, 1.6 J, 2.04 J/cm(2), 51 mW/cm(2) per blister in the prodromal stage and 4.8 J in the crust and secondarily infected stages, plus 1.2 J at the C2-C3 vertebrae
Number of subjects: 232
Study 22047597 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy including acyclovir cream or tablets
Number of subjects: 232
Study 19444123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study 19444123 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study 19441264 — intervention group
Group type: COMPARATOR
Intervention: Group A: Standard polymerization (Control) - Exposure for 20 seconds at 700 mW/cm2
Number of subjects: 120
Study 19441264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Step polymerization - Exposure for 10 seconds at 100 mW/cm2 then 20 seconds at 700 mW/cm2
Number of subjects: 120
Study 19441264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Pulse polymerization - Exposure for 20 cycles, each cycle consists of 1 second at 700 mW/cm2 then 0.25 second at 0 mW/cm2
Number of subjects: 120
Study 19441264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: Ramp polymerization - Exposure for 10 seconds with a slow rise of the intensity to reach 700 mW/cm2 then 20 seconds at 700 mW/cm2
Number of subjects: 120
Study 15842517 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 0
Study 15842517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (120 mg three times daily)
Number of subjects: 0
Study 15109758 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's patients
Number of subjects: 24
Study 15109758 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 24
Study 11742909 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 1,000 microg/d for 4 months
Number of subjects: 87
Study 11742909 — intervention group
Group type: COMPARATOR
Intervention: Inhaled bronchodilator therapy (control group)
Number of subjects: 87
Study 9031898 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM (lansoprazole 30 mg once a day for 1 week, azithromycin 500 mg once a day for 3 days, metronidazole 250 mg twice a day for 3 days)
Number of subjects: 60
Study 9031898 — intervention group
Group type: COMPARATOR
Intervention: OCT (omeprazole, clarithromycin, tinidazole)
Number of subjects: 60
Study 9031898 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM
Number of subjects: 60
Study 8339946 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange dye laser (600 nm)
Number of subjects: 14
Study 8339946 — intervention group
Group type: COMPARATOR
Intervention: Blue‐green argon laser (488 and 514.5 nm)
Number of subjects: 14
Study 3090600 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.9 mg
Number of subjects: 0
Study 3090600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31226922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia screen fail
Number of subjects: 11093
Study 31226922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia assessment fail
Number of subjects: 11093
Study 31226922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent feeding restrictions after dysphagia screen or assessment fail
Number of subjects: 11093
Study 27990746 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent group intervention to manage restricted and repetitive behaviours (RRB) in young children with ASD.
Number of subjects: 14
Study 27645372 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the 5‐CNL on all food products in three specific sections (breakfast cereals, sweet biscuits, appetizers)
Number of subjects: 901
Study 27645372 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of the 5‐CNL accompanied by consumer information on use and understanding of the label
Number of subjects: 901
Study 27645372 — intervention group
Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 901
Study 25479206 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty
Number of subjects: 0
Study 25479206 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery (ESS)
Number of subjects: 0
Study 25479206 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22442959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (500 mg)
Number of subjects: 35
Study 20813705 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (CH)
Number of subjects: 34
Study 20813705 — intervention group
Group type: COMPARATOR
Intervention: Non-continuous hemofiltration (NCH)
Number of subjects: 34
Study 20813705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 19038698 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium bifidum and Lactobacillus plantarum 8PA3)
Number of subjects: 66
Study 19038698 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (abstinence plus vitamins)
Number of subjects: 66
Study 19038698 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium bifidum and Lactobacillus plantarum 8PA3) in subgroup of 26 subjects with mild alcoholic hepatitis
Number of subjects: 66
Study 19038698 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (abstinence plus vitamins) in subgroup of 26 subjects with mild alcoholic hepatitis
Number of subjects: 66
Study 16815777 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua exercise (walking, jogging, and jumping in water for 30 min each day for 3 days)
Number of subjects: 10
Study 16815777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aqua exercise)
Number of subjects: 10
Study 12502973 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (ARS) with peak airway pressure of 40 cm H2O and PEEP of 15 cm H2O for 10 breaths, then reduced to 5 cm H2O.
Number of subjects: 24
Study 12502973 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) of 5 cm H2O without recruitment.
Number of subjects: 24
Study 12502973 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP) with no PEEP or recruitment maneuver.
Number of subjects: 24
Study 10190532 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive strategy
Number of subjects: 23
Study 10190532 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous transluminal coronary angioplasty
Number of subjects: 23
Study 7848119 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg every other day)
Number of subjects: 22071
Study 7848119 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo (control group)
Number of subjects: 22071
Study 7848119 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 22071
Study 7848119 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene placebo (control group)
Number of subjects: 22071
Study 2335168 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 2335168 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 12
Study 2335168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 12
Study 226735 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg daily
Number of subjects: 16
Study 226735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29543510 — intervention group
Group type: EXPERIMENTAL
Intervention: Open acromioplasty (OSG)
Number of subjects: 87
Study 29543510 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty (ASG)
Number of subjects: 87
Study 29543510 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy group (PTG)
Number of subjects: 87
Study 27093503 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL)
Number of subjects: 34
Study 27093503 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngoscope (CL)
Number of subjects: 34
Study 24947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg/d
Number of subjects: 0
Study 24947443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23176247 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids, γ‐linolenic acid, and antioxidants
Number of subjects: 272
Study 20007824 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral drusen associated with CFHY402H (CC versus TT genotypes)
Number of subjects: 1107
Study 20007824 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with CFHY402H (CC versus TT genotypes)
Number of subjects: 1107
Study 20007824 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with presence of 20 or more small, hard macular drusen
Number of subjects: 1107
Study 20007824 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular drusen >63 microm associated with peripheral drusen
Number of subjects: 1107
Study 20007824 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 or more small, hard macular drusen per eye
Number of subjects: 1107
Study 18387797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 100 microg twice daily
Number of subjects: 81
Study 18387797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 microg twice daily
Number of subjects: 81
Study 18387797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18387797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 mg/day (early treatment group)
Number of subjects: 81
Study 18387797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 mg/day (established symptoms)
Number of subjects: 81
Study 18387797 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 81
Study 15761413 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus casei (n = 254)
Number of subjects: 541
Study 15761413 — intervention group
Group type: COMPARATOR
Intervention: Nonprobiotic yogurt (control group, n = 248)
Number of subjects: 541
Study 12848110 — intervention group
Group type: EXPERIMENTAL
Intervention: NPF Psoriasis Score (NPF-PS)
Number of subjects: 33
Study 12848110 — intervention group
Group type: COMPARATOR
Intervention: PASI
Number of subjects: 33
Study 12848110 — intervention group
Group type: COMPARATOR
Intervention: Physician's Global Assessment (PGA)
Number of subjects: 33
Study 10327094 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based programme (experimental group)
Number of subjects: 100
Study 10327094 — intervention group
Group type: COMPARATOR
Intervention: Outpatient or day hospital therapy (control group)
Number of subjects: 100
Study 7562021 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2a-interferon (alpha 2a-INF) in combination with vinblastine
Number of subjects: 30
Study 7562021 — intervention group
Group type: COMPARATOR
Intervention: radical nephrectomy and extended lymphadenectomy
Number of subjects: 30
Study 2140375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic REM sleep induction test in depressed patients
Number of subjects: 50
Study 2140375 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic REM sleep induction test in eating disorder patients
Number of subjects: 50
Study 2140375 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic REM sleep induction test in control subjects
Number of subjects: 50
Study 7322956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 1 week
Number of subjects: 9
Study 7322956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 6 weeks
Number of subjects: 9
Study 7322956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment for 2, 4, and 6 weeks
Number of subjects: 9
Study 7322956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment
Number of subjects: 9
Study 6428643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 107
Study 6428643 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 107
Study 6428643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Pancreatic Function Test
Number of subjects: 107
Study 6428643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CT with either ultrasound or oral pancreatic function test
Number of subjects: 107
Study 30741877 — intervention group
Group type: EXPERIMENTAL
Intervention: PJT-100
Number of subjects: 38
Study 30741877 — intervention group
Group type: EXPERIMENTAL
Intervention: PJT-80
Number of subjects: 38
Study 30741877 — intervention group
Group type: EXPERIMENTAL
Intervention: PJT-65
Number of subjects: 38
Study 30741877 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 38
Study 30536572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring over 7 days
Number of subjects: 233
Study 30536572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 233
Study 30536572 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump use
Number of subjects: 233
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 35
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: Single HPV 16
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: Single HPV 35
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 31/33/35 group
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 18/45/51/52 group
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 39/56/58/59/66/68 group
Number of subjects: 820
Study 29569718 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple infections with HPV 16
Number of subjects: 820
Study 25916689 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors (BCS)
Number of subjects: 127
Study 25916689 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Stigma subscale of BI after Breast Cancer Questionnaire
Number of subjects: 127
Study 25916689 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dryness, body stigma, relationship satisfaction
Number of subjects: 127
Study 24281411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 141
Study 24281411 — intervention group
Group type: COMPARATOR
Intervention: Self-help control group
Number of subjects: 141
Study 22836303 — intervention group
Group type: EXPERIMENTAL
Intervention: PerMIT-guided management
Number of subjects: 26
Study 22836303 — intervention group
Group type: EXPERIMENTAL
Intervention: PerMIT S‐warfarin plasma concentration model
Number of subjects: 26
Study 20434827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone/misoprostol (MM) - 200 mg mifepristone orally followed by 400 microg misoprostol vaginally after 36-48 hours, with up to three additional doses of 400 microg misoprostol every 12 hours
Number of subjects: 210
Study 20434827 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic injection of ethacridine lactate (EL) - 100 mg ethacridine lactate
Number of subjects: 210
Study 18047001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 52
Study 18047001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18047001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMC and placebo)
Number of subjects: 52
Study 16566375 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 147
Study 16566375 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking during pregnancy
Number of subjects: 147
Study 11980761 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative laparoscopy
Number of subjects: 3611
Study 11980761 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 3611
Study 10550131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Double the dose and intensity of cyclophosphamide (4 courses)
Number of subjects: 2548
Study 10550131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Same dose of cyclophosphamide as in Group 1 (2 courses, intensified)
Number of subjects: 2548
Study 10550131 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Double the dose of cyclophosphamide (intensified and increased)
Number of subjects: 2548
Study 10550131 — intervention group
Group type: COMPARATOR
Intervention: Control Group (B-22 standard therapy)
Number of subjects: 2548
Study 7541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 Mio KIU loading dose before sternotomy, followed by 0.5 Mio KIU/h infusion until end of surgery; 2 Mio KIU added to priming volume)
Number of subjects: 110
Study 7541637 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 110
Study 7541637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 2192440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ) 150 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Number of subjects: 98
Study 2192440 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (PIP) 200 mg/kg/day + Flucloxacillin (FLUC) 50 mg/kg/day
Number of subjects: 98
Study 2192440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ)
Number of subjects: 98
Study 2192440 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (PIP)
Number of subjects: 98
Study 371036 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz
Number of subjects: 18
Study 371036 — intervention group
Group type: COMPARATOR
Intervention: clonidine
Number of subjects: 18
Study 31584453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with load (5% of body weight) on the nonparetic limb
Number of subjects: 38
Study 31584453 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without load
Number of subjects: 38
Study 31584453 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 38
Study 30350154 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) - 2×30 breaths, 40% maximal inspiratory pressure
Number of subjects: 8
Study 30350154 — intervention group
Group type: COMPARATOR
Intervention: SHAM - 2×30 breaths, 15% maximal inspiratory pressure
Number of subjects: 8
Study 28508398 — intervention group
Group type: EXPERIMENTAL
Intervention: PFME alone
Number of subjects: 49
Study 28508398 — intervention group
Group type: EXPERIMENTAL
Intervention: PFME + BF
Number of subjects: 49
Study 28508398 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 25655792 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month supervised exercise programme including aerobic and strength exercises
Number of subjects: 66
Study 25655792 — intervention group
Group type: COMPARATOR
Intervention: Usual care for cancer: optimized usual drug therapies and strengthening of self-care
Number of subjects: 66
Study 25655792 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month supervised exercise programme
Number of subjects: 66
Study 24736930 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 185
Study 24736930 — intervention group
Group type: COMPARATOR
Intervention: Standard open discectomy
Number of subjects: 185
Study 22856633 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02 (intranasal formulation of azelastine hydrochloride and fluticasone propionate)
Number of subjects: 779
Study 22856633 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 779
Study 22856633 — intervention group
Group type: COMPARATOR
Intervention: Azelastine (AZ)
Number of subjects: 779
Study 22856633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study 22856633 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 779
Study 18854339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (n=48)
Number of subjects: 99
Study 18854339 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 99
Study 17515294 — intervention group
Group type: EXPERIMENTAL
Intervention: Devasid 250 mg/5 ml (test preparation)
Number of subjects: 24
Study 17515294 — intervention group
Group type: COMPARATOR
Intervention: 375 mg/7.5 ml (reference preparation)
Number of subjects: 24
Study 17515294 — intervention group
Group type: EXPERIMENTAL
Intervention: Devasid (test preparation)
Number of subjects: 24
Study 15354030 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RST)
Number of subjects: 18
Study 15354030 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18